Ask around a menopause forum about red clover or flaxseed and you will get two kinds of answer. Some women say a plant supplement changed their weeks. Others say they took the same thing, at the same dose, for the same length of time, and felt nothing at all.
The clinical trials disagree just as sharply. Ask why, and one explanation comes up more than any other: the bacteria in your gut. It is a genuinely fascinating piece of biology, and it is central to how these plants work. It is also, we think, routinely oversold. Here is the honest version.
The experiment that proves the point
Start with the cleanest result in this field.
Researchers took germ-free rats — animals raised with no gut bacteria whatsoever — and fed them a diet containing ground flaxseed. Flaxseed is the richest dietary source of lignans, the plant compounds thought to have mild estrogen-like effects. Then they measured what those animals actually produced.
The germ-free animals made nothing. Their gut contents held the raw plant compound, but no enterodiol and no enterolactone — the two active “mammalian lignans.” Their urine was, in the authors’ words, devoid of lignans entirely.
Then the researchers colonized a second group with just four bacterial species — Clostridium saccharogumia, Eggerthella lenta, Blautia producta and Lactonifactor longoviformis. Those animals produced the active compounds normally.
This is as close to proof as biology gets: for lignans, the plant supplies a precursor, and bacteria supply the activation. Without the right microbes, nothing happens.
Equol: the same story, in isoflavones
The isoflavone side — soy, and the red clover in our own formula — has an even better-studied version of this.
Red clover’s main isoflavones are biochanin A and formononetin. In the body these are converted to genistein and daidzein. And daidzein can then be transformed one step further, into a compound called equol.
Equol matters because it is more potent than the compound it comes from. All equol isomers bind estrogen receptors more strongly than daidzein does. And crucially, human cells cannot make it. Equol is produced exclusively by gut bacteria — specifically the S-form, which is the only version intestinal bacteria generate.
So some people eat isoflavones and produce equol. Others eat exactly the same isoflavones and produce none. Researchers call them equol producers and non-producers, and the split is real.
How many people are producers? Less settled than you would think
Here the numbers get slippery, and most articles on this subject state them with more confidence than the evidence supports.
Western estimates generally cluster around 25–35%. One US study found 25% among non-vegetarians; another found 27.5% of premenopausal women; another 30% of postmenopausal women. Asian populations are often quoted as much higher — and older studies did report 46% in Japanese and 59% in Korean adults. But larger and more recent Japanese datasets are considerably lower: 28% in a study of 1,345 women, 20% in another of 419.
There is a good reason for the spread, and it is uncomfortable. In 2024, researchers applied five commonly used definitions of “equol producer” to the same 466 healthy adults. The proportion classified as producers ranged from 29% to 47.6% depending purely on which definition was used. A meaningful part of the disagreement in this literature is not biology at all — it is measurement.
The defensible statement is that roughly a quarter to a half of adults are equol producers, and anyone quoting a precise figure should tell you which study and which cut-off they mean.
Having the bacteria is not the same as using them
This is the finding that most changed our thinking, and it rarely appears in supplement marketing.
A 2019 study of Japanese postmenopausal women looked for equol-producing bacteria and found them in 97% of the women tested. Only 22% actually produced equol.
Carrying the organism, in other words, does not mean the pathway runs. The authors concluded that production “might not depend on the quantity, but on the quality” of the bacteria present. Whatever determines who activates these compounds, it is not simply whether you happen to host a particular species — which is precisely why “take this probiotic and you will produce equol” is not a claim anyone can currently support.
Antibiotics leave a long shadow
The lignan side offers the clearest human evidence that this system can be disrupted.
In a study of 2,753 Finnish adults, people who had taken oral antibiotics had significantly lower blood enterolactone than non-users — and the effect was still detectable 12 to 16 months after treatment. It tracked both with the number of courses taken and with how recently.
Related work in the same population found something equally telling: how much lignan people actually ate correlated only weakly with their enterolactone levels. Blood concentrations ranged from zero to over 180 nmol/L. Diet explained very little of that variation, which is what pushed researchers toward the microbiome as the missing variable.
It is not only phytoestrogens
If this were unique to menopause supplements it would be easy to dismiss as special pleading. It is not.
The same pattern appears with ellagitannins — the compounds in pomegranates, walnuts and berries. People fall into three consistent groups depending on which urolithins their bacteria produce, and those groups hold regardless of age, sex, BMI, health status, or which food the compounds came from. Roughly 25–80% fall into one group, 10–50% into another, and 5–25% produce none of these metabolites at all.
Researchers call these patterns metabotypes, and they are now documented across several unrelated classes of plant compound. The underlying phenomenon — that your bacteria decide what a plant food becomes inside you — is not in doubt.
So does this explain why supplements work for some women and not others?
Here is where we part company with most of what is written on this topic.
It is a reasonable hypothesis. It is not an established fact. The distinction matters, and the evidence genuinely does not settle it.
In favor: a randomized, placebo-controlled trial of 96 menopausal women taking isoflavones for six months found significant improvement in hot flashes and sweating only in the equol-producing group. A cross-sectional study of 365 women found that higher dietary daidzein was associated with fewer vasomotor symptoms among producers but not among non-producers.
Against, and it is substantial: the one study that pre-screened women for producer status before randomizing them — rather than splitting them afterwards — found producer status made no difference to the outcome. A systematic review of 42 randomized trials reporting equol status found that 28 were primarily null, and noted that most positive findings came from underpowered secondary analyses. A 2026 systematic review across equol and urolithin metabotypes concluded the evidence for their role in health outcomes is “inconclusive.” Even Kenneth Setchell, who proposed the equol hypothesis in the first place, wrote by 2010 that “the evidence is conflicting on whether there is an advantage to producing equol.”
And there is a competing explanation that deserves more attention than it gets. The Cochrane review of phytoestrogens found placebo groups in these trials improving by anywhere from 1% to 59%. A large part of what looks like mysterious individual variation may simply be the placebo response, which in hot-flash research is famously enormous. Cochrane examined the disagreement between trials directly and could not attribute it to dose, symptom severity or trial quality — and did not identify equol status as the answer either.
What we are not going to tell you
Three things follow from all this, and they are worth stating plainly because the commercial temptation runs the other way.
We are not going to sell you an equol test. At-home tests exist. But there is no validated clinical use for the result, no professional body recommends the testing, the classification shifts by up to 18 percentage points depending on the definition applied, and producer status is only about 82% stable in the same person over one to three years. Producer status also shows no consistent relationship with the things you might expect — no difference in circulating hormones, bone density or body composition.
We are not going to claim a probiotic fixes this. Two controlled human trials have tested this directly — one using bifidobacteria-fermented soymilk, one adding Lactobacillus and Bifidobacterium with a prebiotic to a soy intervention. Neither converted non-producers into producers. Given that most people already carry the relevant bacteria without activating the pathway, simply adding more is not an obvious solution.
We are not going to claim our formula gets around the problem. It does not. If your bacteria do not perform these conversions, a supplement containing lignans and isoflavones cannot force them to.
What it does mean, practically
Three honest takeaways.
Individual variation is real, and biologically grounded. If a plant supplement did nothing for you, that is not necessarily a failure of discipline or a placebo you failed to feel. There are genuine metabolic differences between people in how these compounds are handled.
Uniform results are not a reasonable expectation — and anyone promising them is telling you something the science does not support.
Not every plant works this way. Sage is the useful counter-example: its traditional use for sweating has nothing to do with bacterial activation, and its proposed mechanisms are entirely different. Horsetail’s silicon does not require conversion either. This is one reason we built EQUILI from four plants rather than one — they do not all depend on the same step working.
The gut microbiome is not a marketing flourish in this field. It is the reason a flaxseed lignan is inert until something living acts on it. What remains genuinely unknown is how much of the difference between women it explains — and we would rather say that than pretend otherwise.
Food supplements are not medicines, and individual responses vary.
References
- Woting A, Clavel T, Loh G, Blaut M. Bacterial transformation of dietary lignans in gnotobiotic rats. FEMS Microbiol Ecol. 2010. PubMed 20370826
- Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol. J Nutr. 2002. PubMed 12468591
- Setchell KDR, Clerici C. Equol: history, chemistry, and formation. J Nutr. 2010. PMC2884333
- Setchell KDR, Clerici C. Equol: pharmacokinetics and biological actions. J Nutr. 2010. PMC2884334
- Muthyala RS, et al. Equol, a natural estrogenic metabolite from soy isoflavones. Bioorg Med Chem. 2004. PubMed 15018930
- Setchell KDR, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr. 2006. PubMed 16857839
- Myint K, et al. Comparison of definitions of equol producer status in Japanese adults. 2024. PubMed 38527713
- Takahashi S, et al. Equol producer status among Japanese women. 2022. PubMed 35969890
- Nagata Y, et al. Dietary and lifestyle correlates of urinary excretion of equol in Japanese women. 2008. PubMed 18444135
- Yoshikata R, et al. Relationship between equol producer status and intestinal microbiota. 2019. PubMed 30188331
- Frankenfeld CL, et al. High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br J Nutr. 2005. PubMed 16351761
- Mayo B, Vázquez L, Flórez AB. Equol: a bacterial metabolite from the daidzein isoflavone. Nutrients. 2019. PMC6770660
- Matthies A, Blaut M, Braune A. Isolation of a human intestinal bacterium capable of daidzein and genistein conversion. Appl Environ Microbiol. 2009. PubMed 19139227
- Maruo T, et al. Adlercreutzia equolifaciens gen. nov., sp. nov., an equol-producing bacterium isolated from human faeces. Int J Syst Evol Microbiol. 2008. PubMed 18450717
- Kilkkinen A, et al. Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol. 2002. PubMed 11867359
- Kilkkinen A, et al. Determinants of serum enterolactone concentration. Am J Clin Nutr. 2001. PubMed 11382665
- Setchell KDR, et al. Bioavailability of pure isoflavones and analysis of commercial soy isoflavone supplements. J Nutr. 2001. PubMed 11285356
- Jou HJ, et al. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynaecol Obstet. 2008. PubMed 18395723
- Newton KM, et al. Equol production, S-equol serum levels, and vasomotor symptoms. Menopause. 2015. PubMed 25380274
- Weaver CM, Legette LL. Equol, via dietary soy isoflavones, exerts beneficial effects on bone. J Nutr. 2010. PubMed 20505019
- Birru RL, et al. Equol status and cardiovascular risk factors: a systematic review. J Nutr Sci. 2016. PMC4976117
- Alotaibi B, et al. (Poly)phenol metabotypes and cardiometabolic health: a systematic review. Crit Rev Food Sci Nutr. 2026. PubMed 41236381
- Tomás-Barberán FA, et al. Ellagic acid metabolism by human gut microbiota: three urolithin phenotypes. J Agric Food Chem. 2014. PubMed 24976365
- Tomás-Barberán FA, et al. Urolithins and the concept of metabotypes. Mol Nutr Food Res. 2017. PubMed 27158799
- Nettleton JA, et al. Effect of soy protein with or without probiotics on urinary estrogen metabolites. J Nutr. 2005. PubMed 15735101
- Tsangalis D, et al. Urinary equol excretion in response to consumption of bifidobacteria-fermented soymilk. Eur J Clin Nutr. 2007. PubMed 17021598
- Lethaby A, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews. 2013. PubMed 24323914
- Atkinson C, et al. Daidzein-metabolizing phenotypes in relation to serum hormones and SHBG. Cancer Causes Control. 2008. PubMed 18478336
This page is for general information and is not a substitute for medical advice. Food supplements should not be used as a substitute for a varied, balanced diet and a healthy lifestyle.